This site is intended for healthcare professionals

Prescribing information for Jardiance (empagliflozin) for Great Britain and Northern Ireland.

This sponsored promotional content has been developed, organised, and funded by the Boehringer Ingelheim and Lilly Alliance and is intended for UK Healthcare professionals only. Promotional information regarding Boehringer Ingelheim and Lilly Alliance products will be discussed. GPnotebook has had no input into the content.

The positive benefits of SGLT2 inhibitors in cardiovascular / renal / metabolic diseases (Promotional, product-related content developed and funded by Boehringer Ingelheim and Lilly Alliance)

In this episode, Dr Yassir Javaid and Dr Janaka Karalliedde discuss the broad benefits of SGLT2 inhibitors from a cardio, renal and metabolic perspective and their impact on people living with type 2 diabetes.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone), or by e-mail: [email protected].

PC-GB-106690 | July 2022

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.


Would you like to receive updates about new podcast episodes by email? (You can unsubscribe at any time)